Holen Sie sich die Stockscreener-App
36.01
3.64%
-1.36
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$37.37
Offen:
$36.55
24-Stunden-Volumen:
1.67M
Relative Volume:
0.64
Marktkapitalisierung:
$6.36B
Einnahmen:
$264.79M
Nettoeinkommen (Verlust:
$-14.36M
KGV:
-327.36
EPS:
-0.11
Netto-Cashflow:
$-28.11M
1W Leistung:
-10.11%
1M Leistung:
+7.91%
6M Leistung:
+12.46%
1J Leistung:
+114.86%
1-Tages-Spanne:
$35.88
$37.19
1-Wochen-Bereich:
$35.88
$40.99
52-Wochen-Spanne:
$16.21
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Firmenname
Tg Therapeutics Inc
Sektor
Branche
Telefon
(212) 554-4484
Adresse
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Vergleichen Sie TGTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
36.01 | 6.36B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-29 | Eingeleitet | TD Cowen | Buy |
| 2023-08-02 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-26 | Fortgesetzt | Jefferies | Buy |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2018-09-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-04-25 | Eingeleitet | Jefferies | Buy |
| 2017-03-06 | Bestätigt | FBR & Co. | Outperform |
| 2016-10-06 | Fortgesetzt | Brean Capital | Buy |
| 2016-05-27 | Eingeleitet | SunTrust | Buy |
| 2015-12-01 | Eingeleitet | FBR Capital | Outperform |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-19 | Bestätigt | Brean Capital | Buy |
| 2014-12-11 | Bestätigt | ROTH Capital | Buy |
| 2014-12-10 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
TG Therapeutics shareholders approve key proposals By Investing.com - Investing.com South Africa
TG Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
TG Therapeutics shareholders approve key proposals - Investing.com
TG Therapeutics at Goldman Sachs Conference: Strategic Growth and Innovations - Investing.com Canada
Transcript : TG Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - marketscreener.com
GAMMA Investing LLC Purchases 176,573 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference | TGTX Stock News - GuruFocus
TG Therapeutics (NasdaqCM:TGTX) Stock Rises 13% In Last Month - Yahoo
Kalkine: TG Therapeutics Schedules Fireside Chat at Goldman Sachs Conference Amid FT100 Futures Focus - Kalkine Media
TG Therapeutics CEO Fireside Chat at Goldman's Premier Healthcare Conference: Key Updates Coming - Stock Titan
Two Sigma Advisers LP Sells 214,800 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
LAWSUITS FILED AGAINST U, TGTX and CVNAJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Transcript : TG Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 12 - marketscreener.com
(TGTX) Investment Analysis and Advice - news.stocktradersdaily.com
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference - The Manila Times
TG Therapeutics CEO Fireside Chat: Key Updates Expected at Major Healthcare Conference - Stock Titan
TG Therapeutics shares MS drug trial updates By Investing.com - Investing.com South Africa
TG Therapeutics Announces Data Presentations for BRIUMVI in Mult - GuruFocus
TG Therapeutics shares MS drug trial updates - Investing.com
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting | TGTX Stock News - GuruFocus
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting - The Manila Times
TG Therapeutics Announces Data Presentations for BRIUMVI in - GlobeNewswire
TG Therapeutics: Estimates Could Soon Be Raised Again (NASDAQ:TGTX) - Seeking Alpha
Man Group plc Purchases Shares of 9,589 TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting | TGTX Stock News - GuruFocus
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting - The Manila Times
TG Therapeutics Announces Schedule of Data Presentations - GlobeNewswire
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at ... - Eagle-Tribune
Bank of America Corp DE Has $6.95 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
How To Trade (TGTX) - news.stocktradersdaily.com
Captrust Financial Advisors Sells 22,765 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by BNP Paribas Financial Markets - Defense World
TG Therapeutics' (NASDAQ:TGTX) Weak Earnings May Only Reveal A Part Of The Whole Picture - simplywall.st
Investor Calendar Invites You to the TG Therapeutics, Inc. Third Quarter 2016 Earnings Conference Call and Webcast Live on Monday, November 7, 2016 - ACCESS Newswire
(TGTX) Long Term Investment Analysis - news.stocktradersdaily.com
TG Therapeutics Boosts Retail Sentiment With Q1 Revenue Beat Even As Stock Tumbles On Profit Miss, Conservative Outlook - MSN
Decoding TG Therapeutics Inc (TGTX): A Strategic SWOT Insight - GuruFocus
TG Therapeutics, Inc. (TGTX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
TG Therapeutics raises 2025 guidance to $560M, driven by BRIUMVI adoption - MSN
TG Therapeutics stock sinks on profit miss - MSN
TG Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2025 Earnings Call Transcript - Insider Monkey
TG Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
TG Therapeutics Inc (TGTX) Q1 2025 Earnings Call Highlights: Str - GuruFocus
Jefferies maintains Buy on TGTX stock with $46 target By Investing.com - Investing.com Nigeria
TG Therapeutics Inc (TGTX) Q1 2025 Earnings Call Highlights: Strong BRIUMVI Sales and Increased ... - Yahoo Finance
Finanzdaten der Tg Therapeutics Inc-Aktie (TGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):